RenovoRx (RNXT) investor relations material

Technology and product overview

• Developed TAMP (Trans-Arterial Micro-Perfusion) platform to deliver chemotherapy directly to tumors, reducing systemic toxicity.

• RenovoCath device is FDA-cleared and commercially available for general chemotherapy delivery.

• Focused initially on pancreatic cancer, with ongoing phase III trial and strong preclinical data showing 100x higher local drug concentration.

Commercial progress and financials

• Catheter launched as a standalone device in early 2025, generating $1.1 million in revenue that year.

• Q1 revenue in 2026 exceeded half of 2025’s total, with active customer base growing from 5 to 16 in one year.

• Gross margins are 85%, with cash burn at $1 million/month and break-even projected in the second half of 2027 at $4.5–$5 million annual revenue.

• Peak standalone catheter sales estimated at $400 million recurring revenue, with potential to reach $1–2 billion as indications expand.

Clinical development and milestones

• TIGeR-PaC phase III trial for RenovoGem (catheter + gemcitabine) targets locally advanced pancreatic cancer.

• Interim analysis showed 65% reduction in systemic toxicity and a positive efficacy trend, with six-month survival benefit.

• Full enrollment expected June 2026; final data readout anticipated mid-to-late 2027.

• Additional data presentations and publications planned, with investigator-initiated trials in other cancer types underway.